Our technologies
Cell therapy: OmniCAR
The OmniCAR platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. OmniCAR is a modular, universal CAR platform based on technology licensed from UPenn and Oxford University. It allows unprecedented control and flexibility over current generation CAR-T approaches.
Cell therapy: CellPryme
CellPryme is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. CellPryme-M can be briefly added to standard manufacturing processes. CellPryme-A is used as an adjuvant alongside cellular immunotherapy.
Targeted therapy: PTX-100
PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T cell lymphomas.
Targeted therapy: PTX-200
PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including leukemia; breast cancer and ovarian cancer.
Recent investor briefing
Register for an upcoming briefing or watch a previous session.
OUR PIPELINE
We have a diversified pipeline of later stage and emerging assets developed with world-leading partners including Yale, UPenn, Oxford and Moffitt and Peter MacCallum Cancer Centre.
INVESTOR PORTAL
Here you will find ASX announcements and share price data, along with other key company information. You can also subscribe for email updates and online investor briefings to engage with management directly.
STAY UP TO DATE
Register your details to receive company updates from Prescient Therapeutics
Media
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
7th Mar 2024
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
7th Mar 2024
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
10th Jan 2024
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted that PTX is on the…
Prescient Therapeutics secures speculative buy recommendation from Bioshares
9th Jan 2024
Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company released positive trial results from its Phase Ib study in…
Prescient to advance PTX-100 to phase II for refractory T-cell lymphomas
19th Dec 2023
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…